Abstract
The discovery of mutations that contribute to movement disorders has facilitated the identification of converging pathways and novel therapeutic targets. Successful translation of these research findings into clinical practice will require identification of early markers of disease progression, and recent research indicates that progress is being made in this area.
Original language | English (US) |
---|---|
Pages (from-to) | 65-66 |
Number of pages | 2 |
Journal | Nature Reviews Neurology |
Volume | 8 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2012 |
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience